-
First-trimester contingent screening for trisomy 21 by biomarkers and maternal blood cell-free DNA testing.
Nicolaides KH, Wright D, Poon LC, Syngelaki A, Gil MM.
Ultrasound Obstet Gynecol 2013;42:41-50. pdf -
First-trimester contingent screening for trisomies 21, 18 and 13 by biomarkers and maternal blood cell-free DNA testing.
Nicolaides KH, Syngelaki A, Poon LC, Gil M, Wright D.
Fetal Diagn Ther 2014;35:185-92. pdf -
Maternal serum placental growth factor in prospective screening for aneuploidies at 8-13 weeks' gestation.
Pandya P, Wright D, Syngelaki A, Akolekar R, Nicolaides KH.
Fetal Diagn Ther 2012;31:87-93. -
Noninvasive prenatal testing for fetal trisomies in a routinely screened first-trimester population.
Nicolaides KH, Syngelaki A, Ashoor G, Birdir C, Touzet G.
Am J Obstet Gynecol 2012;207:374. -
Digital PCR for noninvasive detection of aneuploidy: power analysis equations for feasibility.
Evans MI, Wright DA, Pergament E, Cuckle HS, Nicolaides KH.
Fetal Diagn Ther 2012;31:244-7. -
Fetal fraction in maternal plasma cell-free DNA at 11-13 weeks' gestation: effect of maternal and fetal factors.
Ashoor G, Poon L, Syngelaki A, Mosimann B, Nicolaides KH.
Fetal Diagn Ther 2012;31:237-43. -
Chromosome-selective sequencing of maternal plasma cell-free DNA for first-trimester detection of trisomy 21 and trisomy 18.
Ashoor G, Syngelaki A, Wagner M, Birdir C, Nicolaides KH.
Am J Obstet Gynecol 2012;206:322.